These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12735913)

  • 1. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders.
    Takubo H; Harada T; Hashimoto T; Inaba Y; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S31-41. PubMed ID: 12735913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group.
    Ikebe S; Harada T; Hashimoto T; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Takubo H; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S47-9. PubMed ID: 12735915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant syndrome in Parkinson's disease: concept and review of the literature.
    Mizuno Y; Takubo H; Mizuta E; Kuno S
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S3-9. PubMed ID: 12735909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease.
    Hashimoto T; Tokuda T; Hanyu N; Tabata K; Yanagisawa N
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S25-30. PubMed ID: 12735912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of malignant syndrome in Parkinson's disease and related neurological disorders.
    Harada T; Mitsuoka K; Kumagai R; Murata Y; Kaseda Y; Kamei H; Ishizaki F; Nakamura S
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S15-23. PubMed ID: 12735911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention and treatment of malignant syndrome in patients with Parkinson's disease].
    Kuno S
    Nihon Rinsho; 2004 Sep; 62(9):1721-4. PubMed ID: 15462391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study.
    Takubo H; Shimoda-Matsubayashi S; Mizuno Y
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S43-6. PubMed ID: 12735914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
    Kuno S; Mizuta E; Yamasaki S
    Eur Neurol; 1997; 38 Suppl 2():56-9. PubMed ID: 9387804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of malignant syndrome associated with a parkinsonism patient.
    Sanga M; Nomura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Apr; 23(2):91-5. PubMed ID: 12762221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome in advanced Parkinson's disease.
    Gordon PH; Frucht SJ
    Mov Disord; 2001 Sep; 16(5):960-2. PubMed ID: 11746631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rhabdomyolysis as a complication of Parkinson's disease].
    Pozzoni P; Tentori F; Corti M; Pozzi C
    G Ital Nefrol; 2002; 19(1):13-7. PubMed ID: 12165940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.
    Yamawaki Y; Ogawa N
    Intern Med; 1992 Nov; 31(11):1298-302. PubMed ID: 1295627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Malignant syndrome associated with disseminated intravascular coagulation and a high level of amylase in serum, followed by diabetic coma in an elderly patient with Parkinson's disease during L-dopa therapy].
    Saeki H; Muneta S; Kobayashi T
    Nihon Ronen Igakkai Zasshi; 1998 Feb; 35(2):139-44. PubMed ID: 9584493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Case of neuroleptic malignant syndrome following open heart surgery for thoracic aortic aneurysm with parkinson's disease].
    Shinoda M; Sakamoto M; Shindo Y; Ando Y; Tateda T
    Masui; 2013 Dec; 62(12):1453-6. PubMed ID: 24498782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute akinesia in Parkinson disease.
    Onofrj M; Thomas A
    Neurology; 2005 Apr; 64(7):1162-9. PubMed ID: 15824341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.
    Keyser DL; Rodnitzky RL
    Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation].
    Osoegawa M; Motomura S; Yamanaka H; Tamura K; Miyoshi T
    Rinsho Shinkeigaku; 1999 Jun; 39(6):653-7. PubMed ID: 10502992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.
    Rainer C; Scheinost NA; Lefeber EJ
    Postgrad Med; 1991 Apr; 89(5):175-8, 180. PubMed ID: 2008397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.